Clinical trials
Breast Cancer Triple Negative clinical trials
Below are recruiting breast cancer triple negative clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904625Recruiting
Capturing tumor cells in metastatic breast or prostate cancer
This study compares different methods of capturing circulating tumor cells (CTCs) from blood samples in patients with metastatic breast or prostate cancer. It aims to improve how we detect and monitor cancer cells that have spread, which could help guide future treatment decisions.
ToulouseAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Duarte, CaliforniaAges 18 years+ - NCT06920810RecruitingPhase 4
Mistletoe extract plus pembrolizumab for triple-negative breast cancer
This trial tests adding a mistletoe extract (Viscum album) to standard immunotherapy (pembrolizumab) for people with triple-negative breast cancer who have had surgery and radiation. The goal is to see if the combination works better than immunotherapy alone.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06931769Recruiting
Optimizing treatment for stage III triple-negative breast cancer
This trial studies the best ways to give chemotherapy before and after surgery for stage III triple-negative breast cancer. It aims to improve treatment outcomes by using a personalized approach and patient-reported data.
Enschede, OverijsselAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06955156RecruitingPhase 2
Trilaciclib with immunotherapy and chemo for early TNBC
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
BeijingAges 18–75 - NCT06959537RecruitingPhase 1
Combination drug therapy for triple negative breast cancer
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Houston, TexasAges 18 years+ - NCT06962163Recruiting
PET scan study for metastatic triple negative breast cancer
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
Saint-HerblainAges 18 years+ - NCT06963905RecruitingPhase 1/Phase 2
Testing a combination drug for triple-negative breast cancer
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06991790Recruiting
Sacituzumab Govitecan and Toripalimab for First-Line Advanced Triple-Negative Breast Cancer
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
BeijingAges 18–75 - NCT06992336RecruitingPhase 2
Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Guangzhou, GuangodngAges 18–70 - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT07012720Recruiting
Comparing breast cancer treatments before surgery
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
Xi'an, ShaanxiAges 25–75 - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07045311RecruitingPhase 2
JS207 combination therapy for triple-negative breast cancer
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
Hefei, AnhuiAges 18–75 - NCT07046455Recruiting
Trop-2 PET scan for advanced triple-negative breast cancer
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
BeijingAges 18–75 - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07066189Recruiting
Lifestyle, Exercise, and Nutrition for Triple-Negative Breast Cancer
This study tests whether a healthy lifestyle program (diet and exercise) can help improve the results of breast cancer treatment before surgery. It's for women with triple-negative breast cancer who are getting chemotherapy and immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT07069595RecruitingPhase 2
Blood test for breast cancer survivors at risk of recurrence
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer triple negative?
- Yes. Clin2 currently lists 431 recruiting breast cancer triple negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer triple negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer triple negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Triple Negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
- Triple Negative Breast Cancer (TNBC), Early Setting
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.